SCHEMBL6036233

SCHEMBL6036233

O=C(O)CCc1cc(OCCCc2cn(-c3ccc(C(F)(F)F)cn3)nc2C2CCCCC2)nn1-c1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GCGR P47871 2/20 0.38
GIPR P48546 1/20 0.38
S100A4 P26447 1/20 0.35
PTGDR2 Q9Y5Y4 1/20 0.35
GCG P01275 3/20 0.34
LIPE Q05469 1/20 0.33
HCRTR1 O43613 1/20 0.33
PPARD Q03181 2/20 0.33
PPARA Q07869 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
SMO Q99835 1/20 0.33
DGAT1 O75907 1/20 0.33
NR3C1 P04150 1/20 0.33
HDAC4 P56524 1/20 0.33
PTGES O14684 1/20 0.32
CNR2 P34972 2/20 0.32
CNR1 P21554 1/20 0.32
LTB4R Q15722 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6035374 0.88 GCGR (0.37) GCGRGIPRS100A4PTGDR2GCG
SCHEMBL6034689 0.86 PPARD (0.36) GCGRPPARDPPARAHDAC4LTB4R
SCHEMBL6035370 0.86 GCGR (0.37) GCGRS100A4PTGDR2GCGLIPE
SCHEMBL6036323 0.85 LTB4R (0.38) GCGRPPARDPPARAL3MBTL1LTB4R
SCHEMBL6035849 0.84 MLYCD (0.36) GCGRGCGPPARDPPARAL3MBTL1
SCHEMBL1633424 0.84 SMN1; SMN2 (0.37) GCGRPPARDPPARADGAT1NR3C1
SCHEMBL6034858 0.84 GCGR (0.36) GCGRS100A4PTGDR2GCGLIPE
SCHEMBL6035191 0.83 MRGPRX4 (0.35) GCGRPPARDPPARASMOLTB4R
SCHEMBL6036236 0.82 MLYCD (0.35) GCGRGCGPPARDPPARAL3MBTL1
SCHEMBL6035372 0.82 PPARD (0.36) GCGRPPARDPPARADGAT1NR3C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-07-06 US disclosed
EP-1513817-A1 1, 2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY Takeda Pharmaceutical Company Limited (JP) 2005-03-16 EP disclosed
WO-2003099793-A9 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA PHARMACEUTICAL (JP) 2005-02-10 WO disclosed
WO-2003099793-A1 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2003-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity GPR119, SLC5A1, CYP4B1 GCGR 93/4885GIPR 194/4885S100A4 3686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.